CROSS-STANDARD public interest · Home/clinical medical device

China-to-US Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical medical device documentation against US FDA 510(k), registration, listing, US Agent, QMS, and electrical-safety expectations.

Dataset 2026-06-11 Last verified 2026-06-11 15 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline United States (FDA) Gap / action Source + verification date
FDA Medical Device Classification — Overview China's NMPA classifies medical devices into Class I, II, or III (第一类/第二类/第三类) based on risk. Class I (lowest risk) requires only filing/registration with local authorities; Class II requires registration with provincial NMPA; Class III (highest risk, including most implantables and life-sustaining devices) requires registration with the national NMPA. Classification is determined by consulting the "Medical Device Classification Catalogue" (医疗器械分类目录) issued by NMPA.《医疗器械监督管理条例》(国务院令第739号, 2021)
《医疗器械分类目录》(国家药监局公告2017年第104号及后续更新)
《医疗器械注册与备案管理办法》(国家市场监督管理总局令第47号, 2021)		 The FDA classifies medical devices into Class I, II, or III based on the level of risk and the controls necessary to provide reasonable assurance of safety and effectiveness. Class I devices pose minimal risk and are subject to General Controls only. Class II devices pose moderate risk and require Special Controls (often including 510(k) premarket notification). Class III devices pose the greatest risk and generally require Premarket Approval (PMA). Each device is assigned a product code and a regulation number under 21 CFR Parts 862–892, which determines the applicable regulatory pathway.21 CFR Parts 862–892 (Device Classification Regulations)
Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 513
FDA Guidance: "Classify Your Medical Device" (fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device)		 A device's NMPA class does not map directly to its FDA class. Exporters must independently determine the US FDA class and product code via the FDA Product Classification Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) or the "Classify Your Medical Device" tool. The FDA class drives the entire US regulatory pathway (General Controls / 510(k) / PMA), which may be more or less stringent than the NMPA pathway for the same device type. Failure to determine the correct FDA product code is the root cause of most pathway errors for China-origin device exporters.[INFORMATIONAL] Determining the correct FDA device class and product code is the mandatory first step before selecting any US market entry pathway. This determination cannot be substituted by NMPA class alone. U.S. Food & Drug Administration (FDA)2026-06-11 · unverified
FDA Product Code & Regulation Number Assignment China's NMPA does not use a product-code system analogous to the FDA's three-letter product codes. Device types are identified by their category and subcategory codes within the Medical Device Classification Catalogue (医疗器械分类目录). These catalogue codes and the FDA product codes are independent systems; there is no official cross-reference table between them.《医疗器械分类目录》(国家药监局公告2017年第104号及后续更新) Each FDA-regulated medical device is assigned a unique three-letter product code (e.g., DQO, IYO) and a regulation number under 21 CFR Parts 862–892. The product code identifies the device type, its risk class, and the premarket submission type required. Exporters must look up their specific device in the FDA Product Classification Database to find the applicable product code and confirm the required regulatory pathway before preparing any submission.21 CFR Parts 862–892
FDA Product Classification Database: accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm
FDA 510(k) Database (for cleared devices): accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm		 China's NMPA catalogue codes and FDA product codes are entirely separate systems. A device listed under one NMPA catalogue code may correspond to multiple FDA product codes (each with a different class or pathway), or vice versa. Exporters must search the FDA Product Classification Database directly using device type keywords and must not assume a single NMPA catalogue entry maps to a single FDA product code.[INFORMATIONAL] Exporters must query the FDA Product Classification Database to confirm the product code and regulation number for their specific device. This step is required before determining whether a 510(k), De Novo, PMA, or exempt pathway applies. U.S. Food & Drug Administration (FDA) — CDRH Product Classification Database2026-06-11 · unverified
FDA vs NMPA Classification — Risk Class Divergence for the Same Device China's NMPA classification is determined by consulting the Medical Device Classification Catalogue (医疗器械分类目录). The NMPA's three-tier system (Class I/II/III) is based on Chinese regulatory risk assessment, which may reflect different clinical evidence standards, post-market surveillance data, and intended-use definitions compared to the FDA. An NMPA Class II registration does not confer, imply, or substitute for any FDA clearance or approval.《医疗器械监督管理条例》(国务院令第739号, 2021)
《医疗器械分类目录》(国家药监局公告2017年第104号及后续更新)		 The FDA's three-tier risk classification (Class I/II/III) is determined independently of any foreign regulatory body's classification. A device that China's NMPA classifies as Class II (moderate risk) may be classified as Class III (high risk, requiring PMA) by the FDA, or as Class I (low risk, exempt). This divergence is common for combination devices, software as a medical device (SaMD), and devices with novel intended uses. The FDA's classification is binding for US market entry regardless of the NMPA class.FD&C Act Section 513 (21 U.S.C. 360c)
21 CFR Parts 862–892
FDA Guidance: "Software as a Medical Device (SaMD): Clinical Evaluation" (where applicable)
FDA Guidance: "Classify Your Medical Device" (fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device)		 Risk class divergence between NMPA and FDA is a primary compliance risk for China-origin device exporters. A device cleared or registered at NMPA Class II may require a full PMA at FDA Class III, representing a significant increase in time, cost, and clinical evidence requirements. Exporters must not use NMPA class as a proxy for FDA class. The FDA classification must be verified independently for every device and intended use before committing to a regulatory strategy.[INFORMATIONAL] NMPA class and FDA class are independent determinations. A device's NMPA registration class cannot be used to infer its FDA class or the applicable US regulatory pathway. Independent FDA classification verification is required for every device and intended use. U.S. Food & Drug Administration (FDA)2026-06-11 · unverified
Device Labeling Requirements NMPA regulates medical device labeling under the Regulations on the Supervision and Administration of Medical Devices (2021) and the Administrative Measures for Medical Device Instructions and Labels (Order No. 6, 2021). Labels must include device name, model/specification, manufacturer name and address, production date and expiration date or service life, production batch number, registration certificate number, and a list of main materials. Chinese language is mandatory; foreign language may be added but Chinese must be equally prominent. China's UDI system (医疗器械唯一标识) is governed by NMPA's UDI Pilot Implementation Plan and subsequent mandatory rollout schedules, requiring registration in the China UDI Database (UDID).Regulations on the Supervision and Administration of Medical Devices (2021) – Articles 26–29
Administrative Measures for Medical Device Instructions and Labels (NMPA Order No. 6, 2021)
NMPA UDI Pilot Implementation Plan (2019) – Announcement No. 56
NMPA/NHC/NHSA Joint Announcement (March 13, 2026) – Phased UDI rollout: Class III from 2021; 141 Class II types from June 1, 2024; all Class II from June 1, 2027; all Class I from June 1, 2029		 FDA requires device labels to include the device name, manufacturer name and address, directions for use (unless exempt), warnings, contraindications, lot or batch number, model or catalog number, and expiration date where applicable. Labels must be in English. For devices sold in the US, all required label elements under 21 CFR Part 801 must appear on the label or labeling. Class II and III devices and certain Class I devices must also bear a UDI on their label.21 CFR Part 801 – Labeling
21 CFR Part 830 – Unique Device Identification
FDA UDI Rule (78 FR 58786, 2013)
FD&C Act Section 502		 Key gaps exist in three areas: (1) Language — US requires English-only labeling; China requires Chinese as the primary language. Devices entering both markets need bilingual or separate labels. (2) UDI system — US UDI uses FDA's GUDID database (GS1/HIBCC/ICCBBA-based) with Device Identifier (DI) and Production Identifier (PI); China UDI uses NMPA's own UDID database with a different encoding scheme. A device bearing a US UDI does NOT automatically satisfy China UDI requirements, and vice versa — separate UDID registration is required for China. (3) Label content — 21 CFR 801 and NMPA Order No. 6 have overlapping but non-identical mandatory elements; notably, China requires the registration certificate number on the label, which has no US equivalent.[INFORMATIONAL] Devices exported from China to the US must comply with 21 CFR Part 801 (English labeling, mandatory elements) and 21 CFR Part 830 (UDI on label, GUDID registration). Existing China NMPA labels and UDID registration do NOT satisfy US requirements. Separate English-language labels and a GUDID submission are required. Dual-market devices typically require two distinct label versions or a carefully designed bilingual label reviewed by a regulatory specialist. U.S. Food and Drug Administration (FDA)2026-06-11 · unverified
Unique Device Identification (UDI) — Database Submission China's UDI system requires manufacturers and importers to register device identification data in the NMPA UDI Database (UDID, 医疗器械唯一标识数据库) before placing a device on the China market. The UDID is managed by NMPA and uses a similar DI/PI structure but with Chinese-specific encoding standards (primary standards: YY/T 1630-2018 for basic requirements, GB/T 33993-2017 for QR code carriers). UDI implementation is phased: Class III batch 1 from January 1, 2021; Class III batch 2 from June 1, 2022; 141 specified Class II device types from June 1, 2024; all remaining Class II (and Class I IVDs) from June 1, 2027; all Class I from June 1, 2029. The label must carry the UDI in AIDC format and plain text. Unlike the US GUDID which is publicly searchable internationally, China's UDID access and submission portals are primarily Chinese-language and China-entity-oriented.NMPA UDI Pilot Implementation Plan (2019) – Announcement No. 56
NMPA Announcement No. 66 (2019) – Rules for Unique Device Identification System
YY/T 1630-2018 – Basic Requirements for Unique Identification of Medical Devices (primary CN UDI standard)
YY/T 1681-2019 – Basic Terminology of the Unique Identification System for Medical Devices
GB/T 33993-2017 – Product QR Code (carrier standard used in CN UDI)
NMPA/NHC/NHSA Joint Announcement (March 13, 2026) – Phased UDI rollout schedule: Class III from 2021; 141 Class II types from June 1, 2024; all Class II from June 1, 2027; all Class I from June 1, 2029		 US FDA requires manufacturers to submit device identification information to the Global Unique Device Identification Database (GUDID) before distributing a device that must bear a UDI. The GUDID is publicly searchable at accessgudid.nlm.nih.gov. Submission must include the Device Identifier (DI), device description, device class, size, sterility, MRI safety information, and other product attributes. The UDI on the label must be in both human-readable (plain text) and Automatic Identification and Data Capture (AIDC) format (e.g., barcode or RFID). Issuing agencies accredited by FDA include GS1, HIBCC, and ICCBBA.21 CFR Part 830 – Unique Device Identification
21 CFR 830.300 – GUDID submission requirements
FDA UDI Rule (78 FR 58786, September 24, 2013)
FDA Guidance: UDI System: Frequently Asked Questions (2014, updated)		 The US GUDID and China UDID are entirely separate systems with separate registration obligations. A GUDID record does not satisfy UDID requirements and vice versa. Issuing agencies differ: GS1/HIBCC/ICCBBA for US; GS1 is also accepted in China but encoding rules and submission formats diverge. Importers into China must typically appoint a China-registered agent to handle UDID submission. The publicly accessible GUDID (via NLM) has no equivalent open international portal for China's UDID. Compliance for dual-market distribution therefore requires parallel registrations in both databases, potentially with different barcodes or dual-encoded labels if encoding schemes conflict.[INFORMATIONAL] Manufacturers targeting both the US and China markets must complete two separate UDI database registrations: GUDID (FDA) and UDID (NMPA). These are not interchangeable. Dual-market label design should be reviewed by a regulatory specialist to ensure both UDI encoding schemes can coexist on the label, or to determine whether separate labels for each market are more practical. Failure to register in GUDID before US distribution is a prohibited act under the FD&C Act. U.S. Food and Drug Administration (FDA)2026-06-11 · unverified
FDA Establishment Registration & Device Listing (21 CFR Part 807) In China, medical device manufacturers register products with the National Medical Products Administration (NMPA) under the Medical Device Registration and Filing Management Measures. Manufacturers are licensed by provincial or national authorities depending on device classification. There is no concept of annual establishment re-registration with a foreign regulator; NMPA registration is product-centric rather than establishment-centric.《医疗器械注册与备案管理办法》（2021年）
《医疗器械监督管理条例》（国务院令第739号）		 Foreign manufacturers that export medical devices to the United States must register their establishment with FDA annually (between October 1 and December 31 each year) and list every device they manufacture or distribute. Registration and listing are submitted electronically via FDA's Unified Registration and Listing System (FURLS). Failure to register is a prohibited act under 21 U.S.C. §331.21 CFR Part 807
21 U.S.C. §360
21 U.S.C. §331		 Chinese manufacturers exporting to the US must complete a separate, annual FDA establishment registration and device listing process that has no direct parallel in China's domestic regulatory system. Non-compliance renders the device inadmissible at US ports of entry.[INFORMATIONAL] Annual FDA establishment registration and device listing under 21 CFR Part 807 is a mandatory administrative prerequisite for selling medical devices in the United States. Chinese domestic NMPA registration does not satisfy this requirement. U.S. Food & Drug Administration2026-06-11 · unverified
US Agent Designation for Foreign Manufacturers China's regulatory framework does not require foreign manufacturers selling into China to appoint a resident US-style agent within the US. For imported devices sold in China, a Chinese legal agent or authorized representative handles NMPA registration on behalf of the foreign manufacturer, but this is a China-inbound obligation, not an outbound US requirement.《医疗器械注册与备案管理办法》第十三条（境外注册申请人/备案人） Every foreign establishment that registers with FDA must designate a US Agent: a person or firm physically located in the United States who acts as FDA's primary point of contact for the foreign manufacturer. The US Agent must be available during US business hours, assist with device reporting and inspections, and cannot be a mailbox service. The designation is made during FURLS registration and must be kept current.21 CFR §807.40
21 U.S.C. §360(b)(2)		 Chinese manufacturers have no domestic obligation analogous to the FDA US Agent requirement. Entering the US market requires retaining a qualified US-based individual or firm to serve as US Agent — an ongoing operational and contractual commitment with no Chinese-system counterpart.[INFORMATIONAL] Designation of a US Agent under 21 CFR §807.40 is a mandatory, ongoing requirement for any foreign medical device manufacturer registered with FDA. There is no equivalent administrative obligation in China's outbound regulatory framework. U.S. Government Publishing Office — Electronic Code of Federal Regulations (eCFR)2026-06-11 · unverified
MDUFA User Fees for Establishment Registration China's NMPA charges registration fees for product registration dossiers, but there is no annual establishment-level maintenance fee equivalent to MDUFA. Fees in China are assessed per registration application rather than as a recurring annual establishment obligation.《医疗器械注册收费标准》（国家发展改革委、财政部） Under the Medical Device User Fee Amendments (MDUFA), FDA collects an annual establishment registration fee from every domestic and foreign establishment required to register. For FY 2026 the standard fee is $11,423. Payment is required before registration is considered complete; unpaid fees result in the establishment being listed as 'Not Registered' and devices becoming inadmissible.21 U.S.C. §379j (MDUFA)
21 CFR Part 807		 Chinese manufacturers face no recurring annual establishment fee to maintain market access domestically. US market access requires payment of an annual MDUFA establishment registration fee; non-payment blocks registration renewal and renders all listed devices inadmissible.[INFORMATIONAL] Annual MDUFA establishment registration fees are a mandatory recurring cost of US market access for foreign medical device manufacturers. The FY 2026 standard fee is $11,423. Fee amounts are updated each fiscal year and should be confirmed against the current FDA MDUFA fee schedule before submission. U.S. Food & Drug Administration2026-06-11 · unverified
510(k) Premarket Notification — Substantial Equivalence In China, medical devices are subject to NMPA registration (注册) or filing (备案) under a three-class system (Classes I–III). Class I devices may file (备案); Class II and III devices require full registration (注册). The registration dossier must include safety and performance testing, clinical evaluation (or exemption justification), and a conformity declaration to applicable national standards (YY/T or GB standards).《医疗器械监督管理条例》(国务院令第739号, 2021)
《医疗器械注册与备案管理办法》(国家市场监督管理总局令第47号, 2021)
YY/T 0316 (Risk Management, equivalent to ISO 14971)		 Most Class II medical devices must submit a 510(k) Premarket Notification to FDA before marketing in the US. The sponsor must demonstrate substantial equivalence to a legally marketed predicate device by showing the same intended use and same/equivalent technological characteristics (or different characteristics that do not raise new safety/effectiveness questions and perform at least as well as the predicate).21 CFR Part 807 Subpart E
Section 510(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360(k))
FDA Guidance: The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications		 A US 510(k) clearance is a separate regulatory dossier from NMPA registration and does not substitute for it, nor vice versa. Key structural gaps: (1) the 510(k) requires identification of a specific US predicate device, a concept that does not exist in NMPA registration; (2) FDA uses a substantial equivalence standard whereas NMPA evaluates conformity to Chinese national standards and clinical data; (3) timelines differ significantly — FDA target review is 90 days for standard 510(k), while NMPA Class II registration typically takes 60–180 working days at the provincial level; (4) a device cleared via 510(k) in the US still requires a full separate NMPA registration dossier before sale in China.Devices entering the US market that fall under Class II generally require a 510(k) submission demonstrating substantial equivalence to a predicate. This is a distinct process from NMPA registration; both pathways must be pursued independently for dual-market entry. Consult current FDA guidance and 21 CFR Part 807 for specific requirements. U.S. Food and Drug Administration (FDA)2026-06-11 · unverified
Premarket Approval (PMA) — Class III Devices NMPA Class III registration (第三类注册) is the closest Chinese equivalent for high-risk devices. It requires clinical trial data (or exemption approval), full technical dossier, and conformity to applicable YY/T/GB standards. Clinical trials conducted in China must comply with NMPA clinical trial regulations (GCP). NMPA Class III review is conducted centrally by NMPA (not provincial bureaus).《医疗器械监督管理条例》(国务院令第739号, 2021)
《医疗器械注册与备案管理办法》(国家市场监督管理总局令第47号, 2021)
《医疗器械临床试验质量管理规范》(GCP, 2016)		 Class III medical devices (those supporting or sustaining human life, of substantial importance in preventing impairment, or presenting a potential unreasonable risk of illness or injury) require Premarket Approval (PMA) from FDA. The PMA must include valid scientific evidence — typically clinical investigation data — demonstrating reasonable assurance of safety and effectiveness. PMA is the most rigorous FDA premarket pathway.21 CFR Part 814
Section 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360e)
FDA Guidance: Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval		 PMA and NMPA Class III registration are independent pathways with significant structural differences: (1) PMA requires a complete clinical investigation dataset meeting FDA's valid scientific evidence standard; NMPA may accept foreign clinical data under specific conditions but often requires supplemental China-based clinical data; (2) FDA PMA review target is 180 days; NMPA Class III central review typically takes longer and varies; (3) PMA approval does not grant any standing in China's regulatory system, and NMPA registration does not satisfy FDA requirements; (4) post-market obligations (MDR, PMA supplements vs. NMPA change registration) differ substantially in trigger thresholds and timelines.Class III devices intended for the US market require PMA, with clinical evidence as the cornerstone of the submission. This pathway is entirely separate from NMPA Class III registration; manufacturers targeting both markets must complete two independent high-scrutiny regulatory processes. Early engagement with both FDA and NMPA is strongly advisable given the complexity and timelines involved. U.S. Food and Drug Administration (FDA)2026-06-11 · unverified
De Novo Classification — Novel Low/Moderate Risk Devices China does not have a direct equivalent to the De Novo pathway. Novel devices in China are classified by NMPA according to the Medical Device Classification Catalogue (《医疗器械分类目录》). If a device does not fit an existing category, manufacturers may submit a classification confirmation request to NMPA before registration. Novel high-risk devices default to Class III registration. There is no mechanism analogous to De Novo that creates a new predicate category usable by subsequent applicants.《医疗器械分类目录》(国家药监局公告2017年第104号及历次修订)
《医疗器械监督管理条例》(国务院令第739号, 2021)
NMPA Announcement on Standardizing the Classification of Medical Devices (May 11, 2024) — governs classification confirmation (分类界定) procedure for newly developed devices not listed in the Classification Catalogue; submission routed to Center for Medical Devices Standardization Administration (NIFDC)		 The De Novo pathway allows novel medical devices of low to moderate risk (that would otherwise default to Class III due to lack of a predicate) to be classified into Class I or Class II. A successful De Novo request results in a classification order that can itself serve as a predicate for future 510(k) submissions. The submission must include a risk-based classification proposal, performance testing, and a proposed special controls framework.21 CFR Part 860 Subpart D
Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360c(f)(2))
FDA Guidance: De Novo Classification Process (Evaluating Automatic Class III Designation)		 The De Novo pathway has no direct Chinese counterpart. Key gaps: (1) De Novo creates a new US device classification with defined special controls that then functions as an open predicate — this mechanism does not exist in China's catalogue-based system; (2) a De Novo classification order granted by FDA carries no weight with NMPA; (3) novel devices in China must navigate classification confirmation before registration, which is a different process with different evidentiary standards; (4) the concept of special controls as a regulatory instrument for moderate-risk novel devices is absent from NMPA's framework, which relies on standard conformity and clinical data instead.Novel devices without a US predicate that do not warrant Class III PMA review may pursue De Novo classification to obtain a Class I or II designation and establish special controls. The De Novo process is codified at 21 CFR Part 860 Subpart D (final rule October 5, 2021); FDA guidance is "De Novo Classification Process (Evaluation of Automatic Class III Designation)". As of October 1, 2025, De Novo submissions must use the eSTAR electronic format. This pathway is unique to the US regulatory system and has no equivalent in China's NMPA framework; separate classification and registration processes must be followed for each market. U.S. Food and Drug Administration (FDA)2026-06-11 · unverified
Quality System Regulation (QSR) / Quality Management System Regulation (QMSR) China NMPA enforces the Medical Device Production Quality Management Specification (医疗器械生产质量管理规范, NMPA GMP), supported by product-category-specific annexes. ISO 13485:2016 is recognised and often required for export-oriented manufacturers; NMPA GMP is largely aligned with ISO 13485 in structure, covering document control, design control (Class II/III), CAPA, internal audit, supplier management, and post-market surveillance. NMPA site inspections are mandatory before product registration and periodically thereafter.医疗器械生产质量管理规范 (NMPA GMP, 国家药监局公告2022年第55号 and predecessors)
ISO 13485:2016
医疗器械监督管理条例 (2021 revision, State Council Order No. 739)		 FDA 21 CFR Part 820 (QSR) mandated design controls, document controls, CAPA, complaint handling, and production/process controls for medical device manufacturers selling in the US. The QMSR (effective February 2, 2026) aligns Part 820 with ISO 13485:2016, replacing most QSR prescriptive requirements with ISO 13485 by reference, while retaining US-specific provisions such as design history file (DHF), device master record (DMR), device history record (DHR), quality system record (QSR), and MDR linkages. Under QMSR, internal audits, supplier evaluations, and management review records are also subject to FDA inspection (previously shielded under QSR).21 CFR Part 820 (QSR)
FDA Quality Management System Regulation (QMSR) — 21 CFR Part 820 revised, effective February 2, 2026
ISO 13485:2016 (incorporated by reference under QMSR)		 Key gaps for a China-based manufacturer targeting the US market: (1) US-specific record structures — DHF, DMR, DHR, and QSR records must be maintained in the exact formats referenced in 21 CFR 820 / QMSR, not just ISO 13485 equivalents; (2) FDA inspection readiness — as of February 2, 2026, FDA replaced QSIT with Compliance Program 7382.850 for QMSR inspections; FDA investigators may conduct unannounced inspections of foreign facilities, and under QMSR, internal audits, supplier evaluations, and management review records are now within FDA's inspection scope; NMPA inspection experience does not substitute; (3) MDR (Medical Device Reporting, 21 CFR Part 803) integration into the quality system is a US-only obligation; (4) Under QMSR, manufacturers holding ISO 13485 certification will have a structural advantage, but must still map ISO records to QMSR-specific US requirements; (5) English-language documentation and US-qualified management representative are practical necessities for FDA inspections.A China-based manufacturer with NMPA GMP compliance and ISO 13485 certification has a strong quality system foundation, but significant US-specific gaps remain — particularly around DHF/DMR/DHR record formats, FDA inspection readiness under Compliance Program 7382.850 (which replaced QSIT as of February 2, 2026), expanded QMSR inspection scope (internal audits, supplier evaluations, management review records now inspectable), and MDR obligations. Bridging these gaps requires dedicated US QMSR mapping, English documentation, and mock FDA inspection preparation. This information is provided for general reference only and does not constitute legal or regulatory advice. U.S. Food and Drug Administration (FDA) / Electronic Code of Federal Regulations (eCFR)2026-06-11 · unverified
Design Controls NMPA GMP Chapter 5 (Design and Development) and ISO 13485:2016 clause 7.3 require similar design control elements for Class II and III devices in China: design inputs, outputs, review, verification, validation, and change control. The NMPA Technical Review Guidelines and product-specific guidance documents set additional design documentation requirements for 510(k)/PMA equivalents (NMPA registration dossier). Design validation in China typically relies on national standards (YY/T) and NMPA-accepted test reports rather than FDA-style usability/human factors studies.医疗器械生产质量管理规范 第五章 设计和开发 (NMPA GMP Chapter 5)
ISO 13485:2016 Clause 7.3
YY/T series national standards (product-specific)
NMPA Technical Review Guidelines (各适用产品指导原则)		 Under QMSR (21 CFR Part 820, effective February 2, 2026), design controls are no longer governed by the former standalone §820.30 (now reserved/retired). Design and development requirements are incorporated by reference through ISO 13485:2016 §7.3, which requires a documented design and development process covering: design planning, design inputs, design outputs, design review, design verification, design validation (including clinical/usability evaluation), design transfer, design changes, and the Design History File (DHF). Applies to Class II and III devices, and Class I devices with automated functions. The DHF must demonstrate that the device was designed in accordance with the approved design plan and applicable regulations.21 CFR Part 820 QMSR (effective February 2, 2026) — §820.30 retired/reserved under QMSR
ISO 13485:2016 §7.3 Design and Development (incorporated by reference into QMSR)
FDA Guidance: Design Controls for Medical Devices (1997)
IEC 62366-1:2015 (usability engineering, referenced in FDA guidance)		 Key gaps for design controls: (1) DHF format and completeness — the US DHF is a specific FDA-auditable file linking every design stage; NMPA design files serve a similar purpose but may lack the explicit traceability linkages FDA expects; (2) Human factors / usability engineering — FDA requires documented summative usability testing per HFE guidance and IEC 62366 for devices with user interfaces; this is not consistently required in NMPA submissions; (3) Design validation scope — FDA validation must demonstrate the device meets user needs and intended use under actual or simulated use conditions, including worst-case; NMPA validation often relies on type-testing against YY/T standards; (4) Design transfer records — FDA expects documented evidence that design outputs are correctly translated into production specifications (DMR); this linkage is often implicit in CN practice; (5) Software documentation — FDA expects IEC 62304 lifecycle documentation for software-containing devices, with explicit hazard analysis linkages.Chinese manufacturers experienced with NMPA GMP and ISO 13485 design controls have a solid structural basis but will typically need to reconstruct or reformat their design documentation into explicit US DHF structures, add summative usability testing, and ensure design validation covers actual-use conditions rather than type-test equivalence alone. Software device manufacturers face additional IEC 62304 documentation requirements. This information is provided for general reference only and does not constitute legal or regulatory advice. U.S. Food and Drug Administration (FDA) / Electronic Code of Federal Regulations (eCFR)2026-06-11 · unverified
Electrical Safety — ANSI/AAMI ES60601-1 (US National Deviation of IEC 60601-1) GB 9706.1-2020 is China's national standard for general requirements for basic safety and essential performance of medical electrical equipment, aligned to IEC 60601-1 Ed.3 (with minor Chinese deviations). It became mandatory for new product registrations as of 2023-05-01 (per NMPA Announcement No. 14 of 2023, March 16, 2023; superseding GB 9706.1-1995 which was based on IEC 60601-1 Ed.2). NMPA (National Medical Products Administration) registration requires testing against GB 9706.1-2020 by a CNAS-accredited or NMPA-designated laboratory. Test reports and technical dossiers are submitted as part of the medical device registration dossier (Class II/III). The Chinese edition follows IEC 60601-1 Ed.3 structure closely, making cross-recognition partially feasible, but a separate Chinese test report to GB 9706.1-2020 is still required.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01)
NMPA Medical Device Registration Regulations (Order No. 47, 2021)		 ANSI/AAMI ES60601-1 is the US national adoption of IEC 60601-1 (3rd edition) with US-specific deviations (amendment differences noted in Annex B of the AAMI publication). It covers general requirements for basic safety and essential performance of medical electrical equipment. For FDA market entry, manufacturers may use conformity to FDA-recognized consensus standards; ANSI/AAMI ES60601-1 is listed in FDA's Recognized Consensus Standards database as a voluntary consensus standard. Conformity may be declared via an Accession Declaration of Conformity (DoC) submitted with the 510(k) or PMA, or cited in a De Novo request. Third-party testing by an OSHA-accredited NRTL (e.g., UL, TUV SUD, Intertek) is an industry norm for supporting the declaration. Key US deviations include different grounding/earthing requirements and specific clauses on mains voltage tolerances.ANSI/AAMI ES60601-1:2005/(R)2012 and A1:2012/(R)2017 and A2:2021 (R)2021 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (US national deviation of IEC 60601-1 Ed.3)
21 CFR Part 820 (Quality System Regulation / QMSR)
FDA Recognized Consensus Standards Database (ANSI/AAMI ES60601-1 listed)
FDA Guidance: Use of Consensus Standards in Premarket Submissions		 Both US (ANSI/AAMI ES60601-1) and CN (GB 9706.1-2020) are rooted in IEC 60601-1 Ed.3, so the core technical requirements substantially overlap. Key gaps: (1) US requires testing by an OSHA-recognised NRTL and a Declaration of Conformity filed with FDA; CN requires testing by a CNAS/NMPA-designated lab — reports are not mutually recognised. (2) ANSI/AAMI ES60601-1 carries US national deviations (Annex B) not present in GB 9706.1-2020, particularly on grounding and mains voltage tolerances; a gap analysis against the specific US deviations is needed. (3) FDA submission (510(k)/PMA/De Novo) must cite the US edition specifically; GB reports citing the Chinese edition alone are insufficient. (4) Practical timeline: commissioning a separate US NRTL test report is a market-variable cost and timeline; indicative industry ranges cited in secondary sources are approximately USD 10,000–40,000 and 4–16 weeks depending on device complexity and test scope — obtain quotes directly from NRTLs (UL, TÜV SÜD, Intertek, Eurofins) as these figures are not officially published.[INFORMATIONAL ONLY] A device tested to GB 9706.1-2020 has a strong technical foundation for US compliance given shared IEC 60601-1 Ed.3 lineage, but an ANSI/AAMI ES60601-1 test report from a US NRTL is commonly used to support an FDA Declaration of Conformity. The US national deviations (Annex B) should be specifically addressed. This assessment is informational and does not constitute regulatory or legal advice. U.S. FDA Center for Devices and Radiological Health (CDRH) — Recognized Consensus Standards Database; AAMI (Association for the Advancement of Medical Instrumentation)2026-06-11 · unverified
Electromagnetic Compatibility (EMC) — IEC 60601-1-2 (US/FDA Context) GB/T 18268.1-2010 and GB/T 18268.26-2010 are China's national standards for EMC of measuring and control equipment (general and particular requirements), but these are not medical-specific. For medical electrical equipment EMC, China adopted YY 0505-2012, which is based on IEC 60601-1-2 Ed.3 (2007). YY 9706.102-2021 aligns with IEC 60601-1-2:2007 Ed.3.0 and became mandatory for new NMPA registrations from 2023-05-01. NMPA registration requires EMC testing by a CNAS-accredited or NMPA-designated laboratory to YY 9706.102-2021.YY 9706.102-2021 — Medical electrical equipment — Part 1-2: General requirements for basic safety and essential performance — Collateral standard: Electromagnetic disturbances (aligned to IEC 60601-1-2:2007 Ed.3.0, mandatory from 2023-05-01)
YY 0505-2012 — Medical electrical equipment EMC (based on IEC 60601-1-2 Ed.3, legacy)		 IEC 60601-1-2 (4th edition, 2014; collateral standard to IEC 60601-1) specifies EMC requirements — both electromagnetic emissions (radiated and conducted) and immunity — for medical electrical equipment and systems. In the US, FDA recognises IEC 60601-1-2 Ed.4 in its Recognized Consensus Standards database. Manufacturers declare conformity via a DoC submitted with the premarket submission. The standard imposes a risk-based approach: manufacturers must document an electromagnetic disturbance risk management file. Equipment must meet emission limits aligned to CISPR 11 (industrial/scientific/medical) and immunity tests covering ESD, radiated immunity, EFT/burst, surge, conducted immunity, magnetic fields, and voltage dips/interruptions. The 4th edition introduced more stringent requirements for intended-use environments (home healthcare, professional healthcare, special environments).IEC 60601-1-2:2014 Ed.4 — Medical electrical equipment — Part 1-2: General requirements for basic safety and essential performance — Collateral standard: Electromagnetic disturbances — Requirements and tests
FDA Recognized Consensus Standards Database (IEC 60601-1-2 Ed.4 listed)
47 CFR Part 15 (FCC — additional US radio frequency emission requirements may apply depending on device functionality)		 US FDA recognition of IEC 60601-1-2 Ed.4 and CN use of YY 9706.102-2021 do not reference the same IEC edition because YY 9706.102-2021 aligns to IEC 60601-1-2:2007 Ed.3.0. Key gaps: (1) Test reports are not mutually recognised — US requires testing by an OSHA-accredited NRTL or equivalent accredited lab for FDA submission; CN requires a CNAS/NMPA-designated lab. (2) FCC Part 15 (47 CFR Part 15) emission requirements apply in the US to devices that incidentally emit radio frequency energy as digital devices; however, specialized medical digital devices used at the direction of or under the supervision of a licensed health care practitioner are exempt from FCC Part 15 subpart B requirements per 47 CFR §15.103(c) — applicability must be assessed per device type and intended use. (3) IEC 60601-1-2 Ed.4 risk management documentation expectations for FDA submissions may exceed the YY 9706.102-2021/Ed.3.0-aligned China dossier evidence. (4) A device tested only to YY 9706.102-2021 may need additional EMC gap testing or documentation to support IEC 60601-1-2 Ed.4 in the US.[INFORMATIONAL ONLY] A device tested to YY 9706.102-2021 (IEC 60601-1-2:2007 Ed.3.0-aligned) for CN registration may have partial technical overlap with US EMC expectations, but IEC 60601-1-2 Ed.4 gaps should be assessed and a separate test report from a US-recognised laboratory may be needed for FDA submission. Additional FCC Part 15 compliance may be required. This assessment is informational and does not constitute regulatory or legal advice. U.S. FDA Center for Devices and Radiological Health (CDRH) — Recognized Consensus Standards Database; IEC (International Electrotechnical Commission)2026-06-11 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.